YHJ-7-52

YHJ-7-52 is a small molecule compound described in scientific literature as a selective inhibitor of matrix metalloproteinase 2 (MMP2). It is not an approved pharmaceutical drug and does not have any known brand names or commercial formulations. The compound has been studied primarily in preclinical research settings for its potential to modulate extracellular matrix remodeling by inhibiting MMP2 activity, which may be relevant in diseases such as cancer metastasis, fibrosis, and other pathological conditions involving tissue remodeling. There is no evidence that YHJ-7-52 has advanced to clinical trials or human use.